JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $33 from $40 and keeps an Underweight rating on the shares, primarily due to more conservative RSV and influenza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback